Business Context and Reporting Period
The filing is an annual report on Form 10-K for Intrexon Corporation, not Precigen, Inc., for the fiscal year ended December 31, 2015. The requested “2015 Q4” period is covered in the filing’s unaudited quarterly data. Intrexon applies synthetic biology technologies through exclusive channel collaborations, licensing arrangements, joint ventures, acquisitions, and product and service businesses spanning health, food, energy, environment, and consumer markets.
The company reported one operating segment. Key subsidiaries and interests included Trans Ova, Okanagan Specialty Fruits, Oxitec, AquaBounty, and BioPop. As of December 31, 2015, Intrexon owned approximately 63% of AquaBounty.
Financial Results and Key Metrics
| Metric | 2015 | 2014 | Change |
|---|---|---|---|
| Total revenue | $173.6 million | $71.9 million | +141.4% |
| Collaboration and licensing revenue | $87.8 million | $45.2 million | +94.2% |
| Product revenue | $41.9 million | $11.5 million | More than 200% |
| Service revenue | $42.9 million | $14.8 million | +190.8% |
| Operating loss | $(146.9) million | $(70.0) million | Loss increased 109.9% |
| Net loss attributable to Intrexon | $(84.5) million | $(81.8) million | Loss increased 3.3% |
| Net loss per share | $(0.76) | $(0.83) | Improved |
| Research and development expense | $147.5 million | $59.0 million | +150.0% |
| Selling, general and administrative expense | $109.1 million | $63.6 million | +71.3% |
| Operating cash flow | $35.7 million | $(19.9) million | Improved by $55.5 million |
The annual operating margin was approximately negative 84.6%, compared with negative 97.3% in 2014. The net loss attributable to Intrexon margin was approximately negative 48.7%, compared with negative 113.8% in 2014. Despite substantial revenue growth, operating expenses expanded faster than revenue and the company remained significantly unprofitable.
Fourth-quarter 2015 revenue was $41.5 million, operating loss was $34.4 million, net loss attributable to Intrexon was $32.7 million, and basic loss per share was $0.28. Fourth-quarter revenue declined from $53.4 million in the third quarter but exceeded $31.1 million in the fourth quarter of 2014.
Liquidity, Capital Resources, and Balance Sheet
| Metric | December 31, 2015 | December 31, 2014 |
|---|---|---|
| Cash and cash equivalents | $135.8 million | $27.5 million |
| Short-term and long-term investments | $208.0 million | $115.6 million |
| Equity securities | $83.7 million | $164.9 million |
| Total assets | $982.0 million | $576.3 million |
| Total liabilities | $277.2 million | $167.0 million |
| Deferred revenue | $197.7 million | $113.2 million |
| Long-term debt, including current portion | $8.5 million | $10.4 million |
| Accumulated deficit | $542.7 million | $458.2 million |
Cash increased by $108.3 million during 2015. Financing activities provided $333.2 million, primarily from two public offerings that generated $328.2 million of net proceeds. Investing activities used $260.8 million, including $123.9 million for acquisitions, $93.6 million for net purchases of investments, $17.1 million for collaborator securities and warrants, $13.4 million for joint ventures, and $12.7 million for property and equipment.
Management stated that existing cash, investments, and expected receipts from collaborators and subsidiaries should fund operating and capital requirements for at least the next 12 months, although additional capital may be needed if assumptions change. The company also had an at-the-market facility allowing sales of up to $200 million of common stock; no sales had occurred under the facility by year-end.
Material Changes Versus the Prior Comparable Period
- Revenue more than doubled, driven by higher collaboration activity, a full year of Trans Ova results, and product and service revenue from acquired operations.
- Research and development expense increased $88.5 million, including a $59.6 million noncash stock issuance to MD Anderson for an exclusive license covering cancer immunotherapy and CAR T-cell technologies.
- The company acquired ActoGeniX for $72.5 million of total consideration, Okanagan for $40.9 million, and Oxitec for $146.4 million. These transactions materially increased intangible assets and goodwill.
- In June 2015, Intrexon distributed all of its ZIOPHARM shares to shareholders as a special stock dividend and recognized an $81.4 million realized gain. This gain substantially affected other income and reduced the economic comparability of net results.
- Intrexon formed Intrexon Energy Partners II in December 2015, received an $18.0 million technology access fee, retained a 50% interest, and committed to additional capital contributions of up to $10.0 million.
- Deferred revenue increased $84.5 million to $197.7 million, primarily from upfront and milestone payments that had not yet been recognized as revenue.
- Common shares outstanding increased to 116.7 million from 100.6 million, reflecting public offerings, acquisitions, licensing consideration, compensation, and other equity issuances.
- Equity securities declined from $164.9 million to $83.7 million, primarily reflecting the ZIOPHARM distribution and market-value changes.
Guidance, Outlook, Commentary, and Risks
Management expects continued significant losses and increased research and development spending. The company had never generated royalty revenue from products commercialized by collaborators as of the filing date and stated that profitability may not be achieved or maintained. Future revenue depends heavily on new collaborations, milestone payments, reimbursement activity, product and service sales, regulatory approvals, and eventual commercialization by collaborators.
Key regulatory developments included FDA approval of AquaBounty’s AquAdvantage Salmon in November 2015 and prior U.S. and Canadian regulatory clearances for Okanagan’s Arctic apples. These approvals do not ensure commercial success, and additional post-approval, production, labeling, environmental, and market-acceptance requirements remain relevant.
- Collaboration concentration and termination risk: collaborators generally may terminate agreements on approximately 90 days’ notice, and the company relies on collaborators to fund development, obtain approvals, manufacture, market, and commercialize products.
- Regulatory and public-acceptance risk: genetically engineered products, gene therapies, engineered insects, agricultural products, and CAR T-cell therapies face extensive regulation, public opposition, and uncertain approval timelines.
- Development and commercialization risk: no products derived from Intrexon’s collaborations had been commercialized as of year-end, and the company had never received royalty revenue from collaborator product sales.
- Capital and dilution risk: continued operating losses, acquisitions, joint-venture commitments, and research spending may require additional equity or debt financing.
- Marketable securities risk: collaborator equity securities are subject to significant price volatility and liquidity constraints; a 10% increase or 20% decrease in their value would have changed the year-end portfolio value to approximately $92.1 million or $67.0 million, respectively.
- Acquisition and integration risk: 2015 acquisitions added substantial goodwill, intangible assets, operating complexity, and potential impairment exposure.
- Legal contingency: in February 2016, a jury found Trans Ova and XY, LLC each breached a licensing agreement and found Trans Ova infringed XY’s intellectual property. The jury awarded XY $6.1 million and Trans Ova $0.5 million; additional attorneys’ fees or punitive damages were possible, and the final outcome was uncertain.
- Joint-venture commitments: remaining capital contribution commitments to joint ventures totaled $28.7 million at year-end, excluding other uncertain commitments.
- Control and related-party risk: CEO and Chairman Randal J. Kirk and affiliates beneficially controlled approximately 53% of voting stock, while directors, officers, and 5% holders collectively controlled approximately 56%.
Subsequent events included a February 2016 EnviroFlight acquisition and formation of a feed and fertilizer joint venture with Darling Ingredients, as well as a February 2016 AquaBounty promissory note facility of up to $10.0 million, of which $2.5 million had been borrowed.
Important Facts for Investors to Verify
- Confirm the issuer identity: the supplied filing is for Intrexon Corporation, whereas the request identifies Precigen, Inc.
- Reconcile the sources and sustainability of the $173.6 million of 2015 revenue, particularly collaboration revenue, deferred revenue recognition, and acquired product and service businesses.
- Assess cash burn excluding large upfront collaboration receipts, financing proceeds, and noncash fair-value gains.
- Review the economic impact and accounting treatment of the $81.4 million ZIOPHARM distribution gain and the $66.9 million total appreciation in equity securities reported in other income.
- Evaluate the commercial progress, regulatory status, and funding requirements of major programs, including CAR T-cell therapies, AquAdvantage Salmon, Arctic apples, engineered mosquitoes, and energy bioconversion.
- Review acquisition purchase-price allocations, goodwill and intangible-asset impairment exposure, and the effect of only partial-year consolidation for 2015 acquisitions.
- Quantify potential dilution from the $200 million at-the-market facility, outstanding options and warrants, acquisition consideration, and other equity-based compensation.
- Assess the Trans Ova litigation, joint-venture capital commitments, contingent acquisition payments, and other commitments not included in the contractual-obligations table.
- Confirm management’s liquidity assertion against projected operating losses, research and development expansion, and the timing and reliability of collaborator payments.